Obesity Clinical Trial
Official title:
A Randomized, Cross-Over Trial on the Effects of a Low-Fat Vegan Diet Versus a Mediterranean Diet on Body Weight
Verified date | February 2024 |
Source | Physicians Committee for Responsible Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized, cross-over trial aims to assess changes in body weight, plasma lipids, insulin sensitivity, and postprandial metabolism with a low-fat, plant-based diet and a Mediterranean diet, both followed for 4 months.
Status | Completed |
Enrollment | 62 |
Est. completion date | November 13, 2019 |
Est. primary completion date | November 13, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women age =18 years of age - Body mass index 28-40 kg/m2 Exclusion Criteria: - Diabetes mellitus type 1, history of any endocrine condition that would affect body weight, such as thyroid disease, pituitary abnormality, or Cushing's syndrome - Smoking during the past six months - Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use - Use of recreational drugs in the past 6 months - Use within the preceding six months of medications that affect appetite or body weight, such as estrogens or other hormones, thyroid medications (unstable dose within the preceding 6 months), systemic steroids, antidepressants (tricyclics, MAOIs, SSRIs), antipsychotics, lithium, anticonvulsants, appetite suppressants or other weight-loss drugs, herbs for weight loss or mood, St. John's wort, ephedra, beta blockers - Pregnancy or intention to become pregnant during the study period, as verified by self--- - Unstable medical or psychiatric illness - Evidence of an eating disorder - Likely to be disruptive in group sessions - Already following a low-fat vegan diet or Mediterranean diet - Lack of English fluency - Inability to maintain current medication regimen - Inability or unwillingness to participate in all components of the study - Intention to follow another weight-loss method during the trial |
Country | Name | City | State |
---|---|---|---|
United States | Physicians Committee for Responsible Medicine | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Physicians Committee for Responsible Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body weight | Body weight will be assessed at the baseline and at the completion of both interventions. | Change in body weight from Baseline at 4 months | |
Primary | Plasma lipids | Plasma cholesterol, triglycerides, and HbA1c will be measured in a fasting state. | Change in plasma cholesterol, triglycerides, and HbA1c from Baseline at 4 months | |
Primary | Insulin sensitivity | Insulin sensitivity will be assessed by the HOMA index. | Change in insulin sensitivity from Baseline at 4 months | |
Primary | Metabolism | Participants will be asked to report to the laboratory within 60 minutes of waking and after a 12-hour fast. Following 30 minutes of quiet rest in a dimly lit room, pulse, respiratory rate, and body temperature will be measured. REE will be measured for 20 minutes through indirect calorimetry (Cosmed Quark RMR, Chicago, IL) utilizing a ventilated hood system. The laboratory temperature will be maintained at 23 degrees C throughout, and precautions will be taken to minimize any disturbances that could affect the metabolic rate.
For premenopausal women, measures will be timed so as to occur in the luteal phase of the menstrual cycle. Postprandial metabolism will be measured for three hours after the standard meal. |
Changes in metabolism from Baseline at 4 months | |
Secondary | Levels of Advanced Glycosylation Endproducts (AGEs) | An AGE reader will be used to measure the Levels of the AGEs in the skin | Change in Advanced Glycosylation Endproducts (AGEs) from Baseline at 4 months | |
Secondary | Endothelial function | Endothelial function will be measured using the EndoPAT. | Change in Endothelial function from Baseline at 4 months | |
Secondary | Microbiome analysis | Microbiome analysis will be performed from participant-provided stool sample. Anticipated changes in the dietary intervention group include changes in the microbiome composition that correlate with changes in insulin sensitivity. | Change in Microbiome from Baseline at 4 months | |
Secondary | Dietary Advanced Glycation End Products (AGEs) | Explore the effectiveness of a vegan diet in reducing dietary AGEs. | 16 weeks | |
Secondary | PDI, hPDI, uPDI | Assess the total plant-based index (PDI), healthy PDI, and unhealthy PDI, and their relationship with weight loss. | 16 weeks | |
Secondary | Ultraprocessed foods | The consumption of ultraprocessed foods will be assessed, using the NOVA classification, at baseline and 16 weeks. | 16 weeks | |
Secondary | Carbon Footprint | The greenhouse gas emissions (GHGE) and cumulative energy demand (CED) will be assessed, using the database of Food Impacts on the Environment for Linking to Diets (dataFIELD) and What We Eat In America (WWEIA) database, at baseline and 16 weeks. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |